Lipids & Metabolic

Evolocumab appears to be equally effective at reducing LDL cholesterol and preventing cardiovascular events regardless of a patient’s kidney function, according to a new subanalysis of the FOURIER outcomes study presented at the American Society of Nephrology’s annual Kidney Week in San Diego.

Amgen is slashing the list price of its PCSK9 inhibitor evolocumab (Repatha) by almost 60 percent, the company announced Oct. 24.

Overweight and obese women might face better odds against diabetes, insulin resistance and CVD than men, according to a rodent study out of York University in Toronto.

Managing their high blood pressure is the best way patients with diabetes can avoid hypertensive emergencies, according to research published in Clinical and Experimental Hypertension this fall.

A free phone app helped a low-income, obese patient population achieve clinically meaningful weight loss, researchers from Duke University reported in the American Journal of Preventive Medicine.

Having reduced cardiorespiratory fitness (CRF) is as harmful to survival as coronary artery disease, smoking cigarettes or diabetes, suggests a retrospective study published Oct. 19 in JAMA Network Open.

Bariatric surgery may help reduce cardiovascular events beyond normal treatment with medication and lifestyle modifications for patients with severe obesity and type 2 diabetes, suggests an observational study published in JAMA.

Minnesota’s attorney general filed a lawsuit on Tuesday, Oct. 16, accusing drug manufacturers Sanofi, Novo Nordisk and Eli Lilly of deceptive price increases for insulin.

Children who eat breakfasts high in energy but low in nutrition are likely to see higher cholesterol levels, increased insulin resistance and an elevated risk for cardiovascular complications in the future, according to research out of Spain.

Three men with type 2 diabetes used intermittent fasting to lose weight, lower their blood sugar levels and reverse their dependence on insulin treatment, according to a case study report published in The BMJ.

Rapidly growing rates of obesity and diabetes—already threats to global health—will likely have fatal consequences in the case of a future flu pandemic, the Telegraph reported this week.

The deal Regeneron and Sanofi cut with Express Scripts to lower the prices of their PCSK9 inhibitor in exchange for simpler preauthorization forms has opened the floodgates for another two dozen such deals for the cholesterol-lowering drug class, the New York Times reported.